Observation on the therapeutic efficacy and adverse reactions of low-dose vitamin b6 adjunctive to levetiracetam in the treatment of pediatric epilepsy
小剂量维生素B6辅助左乙拉西坦治疗小儿癫痫的疗效及不良反应观察

摘要

目的 探讨在左乙拉西坦治疗的基础上使用小剂量维生素B6辅助治疗小儿癫痫的治疗效果和不良反应。方法 研究样本收集时间为2025年1月至2025年12月，共收集小儿癫痫患儿90例。根据治疗方案不同对样本进行分组，45例患儿为研究对照组，采用左乙拉西坦进行治疗，其余患儿纳入研究观察组，在左乙拉西坦治疗的基础上，叠加使用小剂量维生素B6。并分别在治疗不良反应发生率、治疗效果、癫痫发作相关指标、神经功能及智力发育评分结果、生活质量评分方面对两组患儿进行比较。结果 观察组患儿治疗有效性较高，不良反应发生率较低（P<0.05）；观察组患儿生活质量、神经功能及智力发育评分显著较高，癫痫发作次数及持续时间明显较短，发作间歇期明显延长（P<0.05）。结论 叠加使用小剂量维生素B6辅助左乙拉西坦治疗小儿癫痫能够限制降低癫痫发作频率，缩短发作时间，改善患儿神经功能，安全性和治疗效果较高。

Abstract

Objective To investigate the therapeutic efficacy and adverse reactions of low-dose vitamin B6 adjunctive therapy combined with levetiracetam in the treatment of pediatric epilepsy.
Methods The study collected samples from January 2025 to December 2025, involving a total of 90 pediatric epilepsy patients. According to different treatment regimens, the samples were divided into groups: 45 patients were assigned to the control group, treated with levetiracetam alone, while the remaining patients were included in the observation group, receiving low-dose vitamin B6 adjunctive therapy in addition to levetiracetam. The two groups were compared in terms of the incidence of adverse reactions, therapeutic efficacy, seizure-related indicators, neurological function and intellectual development scores, and quality of life scores.
Results The observation group demonstrated higher therapeutic efficacy and a lower incidence of adverse reactions (P<0.05). The quality of life, neurological function, and intellectual development scores in the observation group were significantly higher, with significantly shorter seizure frequency and duration, and significantly prolonged seizure intervals (P<0.05).
Conclusion   The adjunctive use of low-dose vitamin B6 with levetiracetam in the treatment of pediatric epilepsy can effectively reduce seizure frequency, shorten seizure duration, improve neurological function, and exhibit high safety and therapeutic efficacy.